Our Episodes
Listen to our episodes, read our episode shownotes, and review our references all on your favorite podcast-streaming platforms:
Links to all of our episodes, the shownotes, and references can also be found below.
Thanks so much for tuning in; We are are so glad you are here.
Looking for a specific episode? Use the search feature below or check out our Rotation Guides!
📋 A quick step for our show notes!
Show notes are — and will always be — completely free. We've just added a quick sign-up so we can get to know who's tuning in.
Why? Because understanding our audience helps us build better episodes, better resources, and a better show for you. Help us help you — it takes 30 seconds, and we promise your info stays with us. No selling, no sharing, no spam. Just better content, coming your way.
Episode 164: CLL Updates Series, Pt. 1 – Frontline Therapy in 2026
This week we kick off a two-part update to our CLL series, covering what has changed in frontline management since our original episodes. Using the case of a 68-year-old man with newly diagnosed, symptomatic CLL, we revisit the essential steps before treatment: confirming an indication to treat, ruling out Richter's transformation, and risk stratification, with the history behind FISH cytogenetics, IGHV status, and the CLL-IPI. We then trace how continuous BTK inhibitors and fixed-duration venetoclax-obinutuzumab displaced chemoimmunotherapy, before digging into the trials reshaping practice in 2026: AMPLIFY, SEQUOIA Arm D, and CLL17. Along the way, we cover the open questions for TP53-aberrant disease and why MRD, although prognostic, is not yet a reliable guide for treatment decisions with novel agents.
If you haven’t done so, be sure to check out our original CLL Series, as these updates will draw on concepts covered previously!
Episode 163: Head and Neck Cancer Series, Pt. 5 – Recurrent, Relapsed, and Metastatic Disease
This week the Head and Neck series turns to what happens when local therapy isn't enough — recurrent, relapsed, and metastatic disease. Using the case of a woman with a laryngeal cancer recurrence, we work through the first and most important question (recurrence versus second primary), the workup and biomarkers that steer therapy, local salvage options, the CPS-driven first-line systemic algorithm, second-line and beyond, the distinct world of nasopharyngeal cancer, oligometastatic disease, and the central role of early palliative and supportive care. As always, if you haven't heard the earlier episodes in this series, start there first.
Episode 162: Head and Neck Cancer Series, Pt. 4 – Discussion with Radiation Oncology
This week the Head and Neck series turns to radiation oncology, with guest Dr. David Palma, a Professor and Radiation Oncologist at the Verspeeten Family Cancer Centre and professor at the Schulich School of Medicine and Dentistry, Western University (London, Ontario). A clinician-scientist who splits his time between clinical-trials research and treating head and neck and lung cancers, David walks us through how radiation actually works and gets planned, the de-escalation question, PET after treatment, larynx preservation, re-irradiation, oligometastatic disease, and the proton-versus-photon debate - all with some of the best analogies we've had on the show.
Episode 161: Career Development Series - Building a Career in Clinical Research
This week, we are so excited to share the third episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis!
For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!
This week, we interview Hanny Al-Samkari, MD as he shares his insights on what constitutes clinical research, what a career in clinical research might look like, and how trainees can get involved in clinical research.
Episode 160: Head and Neck Cancer Series, Pt. 3 – Discussion with ENT
Throughout this series, we have discussed how multidisciplinary the management of head and neck cancer is and the critical role that our surgical colleagues play in the management of this disease. This week, we welcome Dr. Michael Topf, Associate Professor for Associate Professor of Otolaryngology-Head and Neck Surgery at Vanderbilt University Medical Center to our show to share with us how he determines which patients are appropriate for surgery, what his approach is, and so much more. It’s rare that we get insights into the factors that our surgery colleagues think about when determining surgical candidacy and surgical approaches and so get ready for an incredibly informative conversation! Another high yield episode you do not to miss!
Episode 159: Head and Neck Cancer Series, Pt. 2 – Locoregional Disease
This week we get into treatment. Building on Part 1's workup and staging, we walk through three cases to highlight the important distinguishing details: an oral cavity cancer, a locally advanced oropharynx cancer, and a larynx cancer.
Episode 158: Head and Neck Cancer Series, Pt. 1 – Introduction
This week, we kick off our Head and Neck Cancer series. Using the case of a man with a painless neck mass, we build a framework for the whole series.
Episode 157: Immune Thrombocytopenic Purpura Series, Pt 3- Challenging Scenarios in ITP
This week, we put everything we talked about in our ITP series together and talk about how we manage ITP in complicated patient scenarios. Through a case-based discussion, we discuss how to we would approach each of these complicated scenarios. If you haven’t done so already, be sure to check out episodes 155 and 156!
Episode 156: Immune Thrombocytopenic Purpura Series, Pt 2- Relapsed/Refractory
This week, we move to the relapsed/refractory ITP setting, focusing on what options are available to patients after their initial treatment with steroids ± IVIg, which we discussed in Episode 155. If you have not done so already, definitely listen to that episode as we build on the topics discussed here today!
Episode 155: Immune Thrombocytopenic Purpura Series, Pt 1- First Line Management
This week, we go back to Classical Hematology! We previously discussed the initial workup and management of ITP in Episode 009, but now it’s time to dig deeper. What do we do once we make the diagnosis? How do we approach management when we have a new diagnosis?
Episode 154: Ask The Program Directors-The Do’s and Don'ts of Applying to Hematology Fellowship (Career Development Series)
This week, we are so excited to share the second episode of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis!
For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!
With fellowship application season around the corner, we thought that this was the perfect time to understand what program directors are looking for in their applicants. This time, we welcome Dr. Alice Ma, Hematology/Oncology Fellowship Director at UNC, and Dr. Gerald Hsu, Hematology/Oncology Fellowship Director at UCSF. Along with our guest hosts, Nick and Claire, we ask the tough questions that all of wish we could ask but never could. This is an episode you do not want to miss!
Episode 153: Myeloma Capstone, Pt 2 - MRD-Guided Therapy, Maintenance, and Relapsed/Refractory Sequencing
This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part two, we cover three practical and rapidly evolving topics: the role of MRD testing in guiding treatment decisions, how to individualize maintenance therapy in 2026, and how to approach sequencing of CAR-T and bispecific therapies in the relapsed/refractory setting.
In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients.
If you have not already done so, be sure to check out Part 1 of this discussion!
Episode 152: Myeloma Capstone, Pt 1 - Smoldering Myeloma & Frontline Treatment in the Elderly
This week, we kick off the first of our myeloma capstone roundtable discussions with two experts who treat myeloma every single day. We welcome back Dr. Manni Mohyuddin from the Huntsman Cancer Institute at the University of Utah, and introduce a new friend of the show, Dr. Adeel Khan from UT Southwestern. In part one, we tackle two highly practical topics: the AQUILA trial and its real-world implications for smoldering myeloma management, and how to approach frontline therapy in the older myeloma patient.
In this week’s show notes, we summarize the key thoughts about how our experts think about approach to their patients.
Stay tuned for part 2 of this discussion next week!
Episode 151: Myeloma Series, Pt. 11 - Role of bispecific T-cell engagers for relapsed/refractory multiple myeloma (2026)
In this week’s episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don’t want to miss.
If you haven’t done so already, be sure to check out our CAR T episode.
Episode 150: Myeloma Series, Pt. 10 - Role of CAR T for relapsed/refractory multiple myeloma
In this week’s episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don’t want to miss.
Episode 149: Myeloma Series, Pt. 9 - Maintenance for Multiple Myeloma (2026)
This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the patient’s quality of life. We discuss this in detail in this week’s episode!
Episode 148: Myeloma Series, Pt.8- Transplant in Multiple Myeloma (2026)
Throughout this series, we have discussed that for eligible patients, the current standard of care is to take patients for autologous stem cell transplant as consolidation for their multiple myeloma. In this reboot episode, we sit down with two incredible hematologists who specialize in transplant to discuss the real-life decision-making that goes into evaluating each patient. We are so excited to welcome two special guests this week, Dr. Shonali Midha and Dr. Amar Kelkar, joining us from the Dana-Farber Cancer Institute in Boston!
Episode 147: Myeloma Series, Pt. 7 - Transplant Consolidation for Multiple Myeloma (2026)
This week, we discuss the role of the “consolidation” phase of treatment in multiple myeloma, focusing on three key trials: IFM 2009, DETERMINATION, and the MIDAS Trial.
Episode 146: Career Development Series-Choosing Your Ideal Mentor
This week, we are so excited to share the first of our Career Development Series episodes, developed in partnership with The American Society of Hematology, The ASH Trainee Council, and Hematopoiesis!
For years, our listeners have reached out to our show asking for guidance to help navigate their careers. We are so excited to be partnering with an amazing organization like ASH to help make this happen!
This time, we welcome two amazing guests, Dr. Hetty Carraway, Director of the Leukemia Program and the Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute at The Cleveland Clinic, and Dr. Alfred Lee, Chief of Classical Hematology at Yale School of Medicine, for our inaugural episode where we discuss the importance of mentorship and ask them all the questions most of us have always wondered but are too afraid to ask our mentors. A MUST listen for all trainees!
Episode 145: Myeloma Series, Pt. 6 - First line treatment of Multiple Myeloma (2026)
This week, we begin our discussion about treatment of multiple myeloma, focusing on the first-line setting. Once again, a lot has changed in this space over the last few years, most notably the standards of care (now quadruplet regimens instead of triplet regimens!). We break down the data and how to help you practically approach your treatment planning for your patient with newly diagnosed multiple myeloma.
Episode 144: Myeloma Series, Pt. 5 - Myeloma Risk Stratification and Response Criteria (2026)
This week, we introduce a new episode for our myeloma series, this time focusing on risk stratification and response criteria. The initial workup and surveillance labs are expansive, but all of the studies we do have a purpose.
Many present-day studies also use “minimal residual disease” (MRD) testing. What does this mean? How do we use this?
We go through all of this and more in this incredibly high yield episode.
Episode 143: Myeloma Series, Pt. 4 - Myeloma Pharmacology (2025)
We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Episode 142: Myeloma Series, Pt.3 - Management of Smoldering Multiple Myeloma (2025)
The way that we think about smoldering multiple myeloma (SMM) has continued to see evolution in the plasma cell dyscrasia space. If this diagnosis portends a higher risk of developing multiple myeloma, how should we manage patients to prevent possible end-organ damage? Is it a one-size-fits-all approach or are there some patients who are higher risk for progression than others? We cover this and so much more in this new episode!
Episode 141: Myeloma Series, Pt.2 - Intro to MGUS and Smoldering Myeloma (2025)
This week, we continue our updated myeloma series, this time we’ll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!
If you haven’t done so already, we highly recommend listening to episode 140 before jumping into this one!
Episode 140: Myeloma Series, Pt.1 - Intro to Testing and MGUS (2025)
It’s been 3 years since our last myeloma series updates and the reality is, a lot has changed! Instead of releasing an updates episode, we are redoing our prior myeloma series to make sure that you, our listeners, can follow along the way you always have.
In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma cell dyscrasias and having our initial discussion about monoclonal gammopathy of undetermined significance (MGUS).
Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series.
You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart.
Episode 138: Follicular Lymphoma Series, Pt 3 - Relapsed/Refractory Management (non-cellular therapy options)
This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week’s conversation!
Episode 137: Follicular Lymphoma Series, Pt 2. - Front-line Management
This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do.
Episode 136: Introduction to Follicular Lymphoma
This week, we kick off a new series, this time focusing on follicular lymphoma! This series will build on a lot of fundamentals that we discussed in our prior series. In this first episode, we start with an introduction to how to approach management of this disease.
Episode 135: VTE Series - Management of Antiphospholipid Antibody Syndrome
This week, we round out our discussion we started in our prior episode on APLS, this time focusing on management. Stick around until the end to hear Dan and Vivek battle it out about the optimal time to recommend APLS testing for your patients!
If you have not done so already, we highly recommend you check out episode 134 (diagnosis of APLS) prior to jumping into this one!
Looking for an episode not listed above? Click here to peruse through all of our episodes or check out our new Rotation Guides page!